Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
Key facts
- Where
- Calgary, CanadaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 19 years old?
Source: NCT03214354, who can take part
Where in Canada
- Alberta Children's HospitalCalgary, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Calgary
- Trial code
- NCT03214354
- Record updated
- 1 May 2026
- Original description
The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The nonmyeloablative regimen will use alemtuzumab, total body irradiation (TBI) and sirolimus for immune suppression. This study will expand the access of HSCT for patients with SCD who are currently not eligible because of donor restrictions.Read full original descriptionShow less
A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-AID)
The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The nonmyeloablative regimen will use alemtuzumab, total body irradiation (TBI) and sirolimus for immune suppression. This study will expand the access of HSCT for patients with SCD who are currently not eligible because of donor restrictions.
Inclusion: Patients must be ≥ 12 months and < 19 years of age at the time of study enrollment; Patients must have sickle cell disease as defined by hemoglobin electropheresis, as follows:; homozygous Hb S disease (HbSS),; sickle-Hb C disease (HbSC),; sickle beta-plus-thalassemia (HbS/β+), or; sickle beta-null-thalassemia (HbS/βo); Patients must meet standard eligibility criteria to undergo HSCT, including but not limited to one or more of the following:; history of repeated (more than 1) bony (vaso-occlusive) crisis; history of stroke; elevated transcranial Doppler velocity not eligible for hydroxyurea, as per TWiTCH trial (ie. severe vasculopathy); history of acute chest crisis or splenic sequestration crisis; history of priapism in males; history of osteonecrosis; pulmonary hypertension as documented by tricuspid regurgitation jet velocity (TRV) > 2.5 m/s on echocardiogram; red cell allo-immunization (≥ 2 antibodies) during long term transfusion therapy; Sickle complications should be present despite the use of hydroxyurea, but this is not an absolute requirement, if the treating team considers the patient to be at high risk for further crisis episodes.
Exclusion: Patients with known hypersensitivity to sirolimus, its derivatives or to any of its components; Patients who are unable to comply with or follow the study protocol.